GAXOS.AI Reports Increased Losses, Significant Dilution from $5.4M ATM Sales, and Strategic Defense AI Acquisition

summarizeSummary

GAXOS.AI's annual report for fiscal year 2025 reveals a substantial increase in net loss to $4.28 million, up from $3.42 million in 2024, despite a significant revenue jump from $4,027 to $1.93 million, primarily driven by RNK Health and Gaxos Labs subscriptions. The company's cash used in operations also increased to $3.85 million. Critically, subsequent events disclosed include the issuance of 3,096,481 common shares between January 26, 2026, and March 5, 2026, raising $5.4 million through its At-The-Market (ATM) program. This represents a highly dilutive event, increasing outstanding shares by over 30%. Additionally, the company completed a $2.9 million acquisition of a 19.99% stake in America First Defense.AI LLC on March 4, 2026, marking a significant strategic investment. The filing also highlights ongoing risks, including the need for additional financing and the potential for Nasdaq delisting, which could severely impact liquidity and investor confidence.

check_boxKey Events

• Increased Net Loss for FY2025

  The company reported a net loss of $4.28 million for the fiscal year ended December 31, 2025, an increase from $3.42 million in the prior year.

• Significant Revenue Growth

  Revenues surged to $1.93 million in 2025 from $4,027 in 2024, primarily from RNK Health administrative services and Gaxos Labs subscriptions.

• Highly Dilutive ATM Share Sales

  Between January 26, 2026, and March 5, 2026, GAXOS.AI issued 3,096,481 common shares through its ATM program, raising approximately $5.4 million. This represents over 30% dilution to the current outstanding shares.

• Strategic Acquisition in Defense AI

  On March 4, 2026, the company completed the purchase of a 19.99% membership interest in America First Defense.AI LLC for $2.9 million, expanding its portfolio into the defense sector.

auto_awesomeAnalysis

GAXOS.AI's annual report for fiscal year 2025 reveals a substantial increase in net loss to $4.28 million, up from $3.42 million in 2024, despite a significant revenue jump from $4,027 to $1.93 million, primarily driven by RNK Health and Gaxos Labs subscriptions. The company's cash used in operations also increased to $3.85 million. Critically, subsequent events disclosed include the issuance of 3,096,481 common shares between January 26, 2026, and March 5, 2026, raising $5.4 million through its At-The-Market (ATM) program. This represents a highly dilutive event, increasing outstanding shares by over 30%. Additionally, the company completed a $2.9 million acquisition of a 19.99% stake in America First Defense.AI LLC on March 4, 2026, marking a significant strategic investment. The filing also highlights ongoing risks, including the need for additional financing and the potential for Nasdaq delisting, which could severely impact liquidity and investor confidence.